Risk tolerance to MS therapies: Survey results from the NARCOMS registry.

Background: There is little information about risk acceptance of multiple sclerosis (MS) patients to various MS therapies.

Objective: To determine MS patients׳ tolerance to risky therapies and identify associated characteristics.

Methods: MS patients from the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry׳s online cohort were invited to complete questionnaires on decision making and risk tolerance (RT) to two therapeutic scenarios: a theoretical cure for MS [CureMS], with permanent reversal of all MS symptoms but a risk of immediate painless death; and natalizumab [NAT], a real-life scenario with benefits and risks as defined by Phase III trial results.